Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec;43(12):2589-2591.
doi: 10.1111/liv.15762.

Frontline resection or liver transplantation in patients with single-nodule hepatocellular carcinoma

Rui Liao  1 , Manuel Rodríguez-Perálvarez  2   3
Affiliations
Editorial

Frontline resection or liver transplantation in patients with single-nodule hepatocellular carcinoma

Rui Liao et al. Liver Int. 2023 Dec.
No abstract available

PubMed Disclaimer

Comment on

  • Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.
    Pelizzaro F, Trevisani F, Simeon V, Vitale A, Cillo U, Piscaglia F, Missale G, Sangiovanni A, Foschi FG, Cabibbo G, Caturelli E, Di Marco M, Azzaroli F, Brunetto MR, Raimondo G, Vidili G, Guarino M, Gasbarrini A, Campani C, Svegliati-Baroni G, Giannini EG, Mega A, Masotto A, Rapaccini GL, Magalotti D, Sacco R, Nardone G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Pelizzaro F, et al. Liver Int. 2023 Dec;43(12):2762-2775. doi: 10.1111/liv.15719. Epub 2023 Sep 27. Liver Int. 2023. PMID: 37753540

References

REFERENCES

    1. Pelizzaro F, Trevisani F, Simeon V, et al. Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023;(in press).
    1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-693.
    1. Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019;70(5):866-873.
    1. Chu W, Li P, Wu X, Zhang P, Zhou H, Niu B. Risk factors for recurrence beyond Milan criteria after radiofrequency ablation in transplantable small hepatocellular carcinoma. Rev Esp Enferm Dig. 2022;114(10):580-585.
    1. Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208-218.

LinkOut - more resources